Publications dans lesquelles il/elle collabore avec Bonaventura Clotet Sala (64)

2023

  1. Hepatitis delta infection among persons living with HIV in Europe

    Liver International, Vol. 43, Núm. 4, pp. 819-828

2021

  1. Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy: A multinational prospective cohort study

    Annals of Internal Medicine, Vol. 174, Núm. 6, pp. 768-776

2019

  1. Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA

    HIV Medicine, Vol. 20, Núm. 4, pp. 264-273

2018

  1. Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort

    HIV Medicine, Vol. 19, Núm. 4, pp. 252-260

  2. Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens

    HIV Medicine, Vol. 19, Núm. 2, pp. 102-117

  3. Long-term effectiveness of recommended boosted protease inhibitor-based antiretroviral therapy in Europe

    HIV Medicine, Vol. 19, Núm. 5, pp. 324-338

  4. The extent of B-cell activation and dysfunction preceding lymphoma development in HIV-positive people

    HIV Medicine, Vol. 19, Núm. 2, pp. 90-101

2017

  1. Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253

2016

  1. Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: Raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART

    Journal of Antimicrobial Chemotherapy, Vol. 71, Núm. 4, pp. 1056-1062

  2. Host and disease factors are associated with cognitive function in European HIV-infected adults prior to initiation of antiretroviral therapy

    HIV Medicine, Vol. 17, Núm. 6, pp. 471-478

  3. Infection-related and -unrelated malignancies, HIV and the aging population

    HIV Medicine, Vol. 17, Núm. 8, pp. 590-600

  4. Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression: A prospective cohort study

    Medicine (United States), Vol. 95, Núm. 40

  5. Transmission of HIV drug resistance and the predicted effect on current first-line regimens in Europe

    Clinical Infectious Diseases, Vol. 62, Núm. 5, pp. 655-663

2015

  1. Changing utilization of Stavudine (d4T) in HIV-positive people in 2006-2013 in the EuroSIDA study

    HIV Medicine, Vol. 16, Núm. 9, pp. 533-543

  2. Decreasing prevalence of HCV coinfection in all risk groups for HIV infection between 2004 and 2011 in Spain

    Journal of Viral Hepatitis, Vol. 22, Núm. 5, pp. 496-503

  3. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial

    The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 775-784

  4. Executive summary of the GESIDA/National AIDS Plan Consensus Document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2015)

    Enfermedades infecciosas y microbiologia clinica

  5. Liver-related death among HIV/hepatitis C virus-co-infected individuals: Implications for the era of directly acting antivirals

    AIDS, Vol. 29, Núm. 10, pp. 1205-1215

  6. Transmitted drug resistance to rilpivirine in newly diagnosed antiretroviral naive adults

    Clinical Microbiology and Infection, Vol. 21, Núm. 1, pp. 104.e1-104.e5

  7. Use of cohort data to estimate national prevalence of transmitted drug resistance to antiretroviral drugs in Spain (2007-2012)

    Clinical Microbiology and Infection, Vol. 21, Núm. 1, pp. 105.e1-105.e5